YOLFTbeta
Beijing Strong Biotechnologies Inc

Beijing Strong Biotechnologies Inc

300406 · SHE · Healthcare / Diagnostics & Research

12.66CNY-0.03 (-0.24%)

Price History

Full chart

Market Stats

Previous Close12.69
Open12.67
Day Range12.51 – 12.82
52-Week Range10.39 – 14.96
Volume5.34M
Market Cap7.00B
P/E (TTM)31.42
Forward P/E0.00
EPS0.38
Dividend Yield11.31%
Beta0.28
50-Day Avg11.64
200-Day Avg12.31

About

Beijing Strong Biotechnologies,Inc. researches, develops, manufactures, and sells in-vitro diagnostics (IVD) products and services in China and internationally. It provides biochemistry reagents, including liver, renal, lipid, cardiac, diabetes, special protein, tumor marker, pancreas, inorganic, inflammation, TDM, and other panels; and coagulation products, such as prothrombin time, activated partial thromboplastin time, thrombin time, and fibrinogen, as well as antithrombin III, von Willebrand factor antigen, protein S activity, protein C, lupus anticoagulant, fibrin degradation products, and d-dimer. The company also offers blood grouping card comprising ABO blood type anti stereotype detection card, DiaClon ABD-confirmation, and DiaClon ABO/D+ reverse grouping for patients; and automatic coagulation analyzer, automatic biochemistry analyzer, fully automatic chemiluminescence immunoassay analyzer, and automated blood groupings analyzer. It sells its products under the Kingsley and Meichuang brand names. Beijing Strong Biotechnologies,Inc. was founded in 2001 and is based in Beijing, China.

Company Details

  • SectorHealthcare
  • IndustryDiagnostics & Research
  • CEOMr. Wei Liu
  • Employees998
  • HeadquartersKuang Yi Building, Beijing, China, 100191, China
  • Websitehttps://www.bsbe.com.cn

Leadership

  • Mr. Wei LiuCFO & Accounting Supervisor · b. 1969
  • Mr. Jian Min WangSecretary of the Board of Directors · b. 1977
  • Mr. Yi ZhangDeputy General Manager · b. 1972
  • Mr. Qinghai YangDeputy General Manager · b. 1976
  • Mr. Qixin LinDeputy General Manager · b. 1979

Financials

Income Statement

Currency: CNY2011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue275.96M380.14M444.63M508.27M566.20M667.40M694.28M774.18M840.86M848.12M1.60B1.51B1.74B1.66B1.36B
Growth (%)-+37.75%+16.96%+14.32%+11.40%+17.87%+4.03%+11.51%+8.61%+0.86%+88.58%-5.53%+15.27%-4.75%-18.29%
Cost of Revenue108.57M139.30M141.21M146.43M158.99M210.16M195.40M243.78M264.01M328.44M448.50M384.12M445.01M361.88M279.92M
Gross Profit167.40M240.84M303.41M361.84M407.21M457.24M498.88M530.40M576.85M519.67M1.15B1.13B1.30B1.30B1.08B
Gross Margin60.66%63.35%68.24%71.19%71.92%68.51%71.86%68.51%68.60%61.27%71.96%74.58%74.45%78.19%79.35%
Operating Expense51.12M79.38M96.12M123.81M125.09M146.35M175.26M183.12M199.10M366.63M615.01M671.26M702.74M673.00M600.81M
Operating Income116.28M161.46M207.30M238.03M282.12M310.89M323.62M347.28M377.75M153.05M535.87M455.49M593.88M624.05M474.78M
Operating Margin42.13%42.47%46.62%46.83%49.83%46.58%46.61%44.86%44.92%18.05%33.50%30.15%34.10%37.62%35.03%
EBITDA125.70M169.07M216.28M246.53M286.33M310.05M330.82M343.25M381.69M196.05M590.51M554.35M658.03M700.68M357.31M
EBITDA Margin45.55%44.48%48.64%48.50%50.57%46.46%47.65%44.34%45.39%23.12%36.92%36.69%37.78%42.24%26.36%
Net Income100.78M137.01M180.64M210.64M245.04M271.65M273.15M300.67M331.65M112.28M405.65M389.10M523.74M532.64M189.87M
Net Income Margin36.52%36.04%40.63%41.44%43.28%40.70%39.34%38.84%39.44%13.24%25.36%25.75%30.07%32.11%14.01%
R&D9.55M17.61M19.16M26.15M26.61M42.90M53.66M61.04M70.32M79.06M127.01M137.20M162.90M188.53M181.73M
R&D as % of Total Revenue3.46%4.63%4.31%5.14%4.70%6.43%7.73%7.88%8.36%9.32%7.94%9.08%9.35%11.36%13.41%
Interest Expense480.00K353.00K262.00K89.09K94.71K107.01K1.99M3.45M1.38M9.66M22.08M52.64M46.99M47.90M49.44M
Interest Expense % of Total Revenue0.17%0.09%0.06%0.02%0.02%0.02%0.29%0.45%0.16%1.14%1.38%3.48%2.70%2.89%3.65%

Balance Sheet

Currency: CNY2011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets316.70M432.48M520.88M1.04B1.26B1.47B1.78B1.86B2.15B3.96B4.32B4.61B5.18B5.57B5.05B
Total Liabilities28.04M46.81M44.57M57.44M86.56M83.09M248.65M162.52M183.09M540.20M1.41B1.34B1.45B1.44B1.27B
Total Equity288.66M385.67M476.31M987.03M1.18B1.39B1.53B1.70B1.97B3.20B2.87B3.27B3.72B4.14B3.79B
Cash82.41M152.07M187.62M644.62M697.46M792.20M683.09M480.12M225.67M577.19M382.52M340.72M724.04M1.04B539.65M
Total Debt5.00M5.00M--26.50M20.68M61.68M63.98M89.82M300.12M1.12B1.10B1.13B1.13B-
Net Debt-77.41M-147.07M-187.62M-644.62M-670.95M-771.52M-621.41M-416.14M-135.85M-277.07M741.97M761.78M407.62M86.22M524.31M

Cash Flow

Currency: CNY2011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow45.90M125.49M147.19M156.94M142.59M243.21M207.91M256.15M188.60M123.06M341.10M396.17M590.15M614.01M565.11M
Investing Cash Flow-23.98M-20.44M-9.71M-6.69M-53.03M-76.62M-184.19M-243.10M-387.37M-1.08B-1.31B-440.82M-132.27M-18.62M-
Financing Cash Flow-18.81M-35.41M-101.81M306.82M-37.80M-73.12M-131.84M-215.93M-55.75M1.30B776.67M-10.58M-74.76M-176.48M-
Capital Expenditure24.13M20.44M9.89M6.86M53.08M76.62M25.25M73.10M61.41M17.25M65.20M96.48M148.03M67.65M39.24M
Free Cash Flow21.77M105.05M137.30M150.08M89.51M166.58M182.66M183.05M127.19M105.81M275.90M299.69M437.06M546.36M525.87M
Dividends Paid16.67M34.51M95.98M-62.22M74.95M150.25M75.28M74.54M74.54M58.41M58.81M58.60M124.19M537.14M
FCF to OCF47.42%83.71%93.28%95.63%62.77%68.49%87.86%71.46%67.44%85.99%80.88%75.65%74.06%88.98%93.06%
Dividend Paid to FCF76.57%32.85%69.91%-69.51%44.99%82.26%41.12%58.61%70.44%21.17%19.62%13.41%22.73%102.14%

Earnings

Report DateApr 27, 2015Aug 18, 2015Oct 23, 2015Feb 19, 2016Apr 26, 2016Aug 24, 2016Oct 26, 2016Mar 27, 2017Apr 26, 2017Aug 28, 2017Oct 26, 2017Feb 27, 2018Apr 26, 2018Aug 29, 2018Oct 25, 2018Feb 27, 2019Apr 25, 2019Aug 29, 2019Oct 28, 2019Feb 28, 2020Apr 28, 2020Aug 27, 2020Oct 29, 2020Mar 25, 2021Apr 28, 2021Aug 26, 2021Oct 28, 2021Apr 26, 2022Aug 26, 2022Oct 27, 2022Apr 19, 2023Aug 9, 2023Oct 24, 2023Mar 29, 2024Apr 28, 2024Aug 23, 2024Oct 28, 2024Mar 28, 2025Apr 25, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
EPS Estimate--------------------------------------------
EPS Actual0.110.100.120.160.130.110.130.170.100.110.150.180.120.110.160.180.120.140.170.230.030.040.100.040.190.190.150.160.110.180.210.220.220.260.200.220.210.270.140.160.17-0.140.180.18
Surprise--------------------------------------------
TimingAfter-hoursPre-marketAfter-hoursAfter-hoursPre-marketAfter-hoursPre-marketAfter-hoursPre-marketAfter-hoursPre-marketAfter-hoursPre-marketAfter-hoursPre-marketPre-marketAfter-hoursAfter-hoursPre-marketAfter-hoursPre-marketAfter-hoursPre-marketPre-marketAfter-hoursAfter-hoursPre-marketPre-marketPre-marketAfter-hoursPre-marketPre-marketAfter-hoursAfter-hoursPre-market-Pre-market-Pre-market-----

Key Statistics & Ratios

Market Cap7.00B
Enterprise Value7.53B
Trailing P/E31.42
Forward P/E0.00
Price / Sales5.12
Price / Book1.94
EPS0.38
Book Value6.17
Revenue (TTM)1.37B
Gross Profit (TTM)1.09B
EBITDA558.89M
Profit Margin16.47%
Operating Margin37.60%
Return on Equity5.88%
Return on Assets5.97%
Shares Outstanding586.14M
Shares Float215.95M
Beta0.28
Dividend Yield11.31%
Dividend Rate1.35
Payout Ratio2.73%

Dividends

20262×
0.15Sep 3, 20260.70May 29, 2026
20253×
0.20Nov 27, 20250.30Sep 5, 20250.40May 6, 2025
20241×
0.20May 7, 2024
20231×
0.10May 22, 2023
20221×
0.10May 27, 2022
20211×
0.10May 27, 2021
20201×
0.15Apr 24, 2020
20191×
0.15Apr 30, 2019
20181×
0.15May 7, 2018
20171×
0.30Apr 28, 2017
20161×
0.15May 3, 2016
20151×
0.13Apr 20, 2015

Stock Splits

  • May 3, 201620:10
  • Apr 20, 201520:10